This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
SITC 2022
Presentations

SGN-BB228 | Preclinical | Abstract #1201
SGN-BB228 is a first-in-class CD228-targeted costimulatory Antibody Anticalin® bispecific delivering potent and conditional 4-1BB costimulation to tumor-specific T cells

SGN-B6A | Solid Tumors | Abstract #731
A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: Interim results of a Phase 1 study (SGNB6A-001)

Enfortumab Vedotin | Preclinical | Abstract #1187
Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors

SGN-B6A | Preclinical | Abstract #1186
SGN-B6A induces immunogenic cell death as a secondary mechanism of action

SGN-B7H4V | Preclinical | Abstract #1190
SGN-B7H4V induces immunomodulatory changes to the tumor microenvironment and pairs well with an anti-PD1 agent in a preclinical model

SEA-CD40 | Advanced Malignancies | Abstract #705
Phase 2 study of SEA-CD40 combination therapies in advanced malignancies (SGNS40-002, trial in progress)

Research | Abstract #1357
Reversible chemical modulation of antibody effector function maintains anti-tumor activity while mitigating peripheral immune activation

Disitimab Vedotin | Urothelial Carcinoma | Abstract #663
Phase 2 multi-cohort clinical study evaluating Disitamab Vedotin alone and in combination with pembrolizumab in patients with HER2-expressing unresectable or metastatic urothelial carcinoma (rc48g001, trial in progress)